Neuroone Medical Technologies (NMTC) Current Deferred Revenue (2020 - 2022)

Neuroone Medical Technologies' Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $1.5 million for Q3 2022.

• Quarterly Current Deferred Revenue rose 16777.62% year-over-year to $1.5 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $1.5 million (up 16777.62% YoY) and the FY2022 annual result came in at $1.5 million, up 16777.62% from the prior year.
• Current Deferred Revenue was $1.5 million for Q3 2022 at Neuroone Medical Technologies, up from $2248.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $1.5 million in Q3 2022 and bottomed at $2248.0 in Q4 2021.
• A 3-year average of $182199.0 and a median of $13596.0 in 2021 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2021 — Current Deferred Revenue plunged 95.61% — and 2022, when it jumped 16777.62%.
• Neuroone Medical Technologies' Current Deferred Revenue stood at $51160.0 in 2020, then plunged by 95.61% to $2248.0 in 2021, then jumped by 64632.56% to $1.5 million in 2022.
• Business Quant data shows NMTC's Current Deferred Revenue at $1.5 million in Q3 2022, $2248.0 in Q2 2022, and $2248.0 in Q1 2022.